Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone

Journal of Bone and Mineral Research

Volumn 22, Issue 10, 2007, Pages 1510-1517

  Merlotti, Daniela ^a   Gennari, Luigi ^a   Martini, Giuseppe ^a   Valleggi, Fabrizio ^a   De Paola, Vincenzo ^a   Avanzati, Annalisa ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bisphosphonate; Neridronate; Paget's disease of bone; Treatment; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLECALCIFEROL; NERIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; 6 AMINO 1 HYDROXYHEXANE 1,1 DIPHOSPHONATE; 6-AMINO-1-HYDROXYHEXANE-1,1-DIPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARM PAIN; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOCALCEMIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; OUTCOME ASSESSMENT; PAGET BONE DISEASE; PAIN; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE; TREATMENT RESPONSE; COMPARATIVE STUDY; DRUG TOXICITY; ENZYMOLOGY; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; QUALITY OF LIFE; TIME;

AGED; DIPHOSPHONATES; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; OSTEITIS DEFORMANS; PAIN; QUALITY OF LIFE; TIME FACTORS;

EID: 38449091517     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070704     Document Type: Article

References (44)

1. Paget J 1877 On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans 60:37-63.
2. Altman RD 1991 Paget's disease of bone. In: Coe FL, Favus MJ (eds.) Disorders of Bone and Mineral Metabolism. Raven Press, New York, NY, USA, pp. 1027-1064.
3. Gennari L, Merlotti D, Martini G, Nuti R 2006 Paget's disease of bone in Italy. J Bone Miner Res 21:P14-P21.
4. Cooper C, Harvey NC, Dennison EM, van Staa TP 2006 Update on the epidemiology of Paget's disease of bone. J Bone Miner Res 21:P3-P8.
5. Gold DT, Boisture J, Shipp KM, Pieper CF, Lyles KW 1996 Paget's disease of bone and quality of life. J Bone Miner Res 11:1897-1904.
6. Selby PL, Davie MWJ, Ralston SH, Stone MD 2002 Guidelines on the management of Paget's disease of bone. Bone 31:366-373.
7. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
8. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617-627.
9. Ziebland S, Frizpatrick R, Jenkinson C, Mowat A 1992 Comparison of two approaches to measuring change in health status in rheumatoid arthritis: The Health Assessment Questionnaire (HAQ) and modified HAQ. Ann Rheum Dis 51:1202-1205.
10. Bruce B, Fries JF 2003 The Stanford Health Assessment Questionnaire: A review of its history, issues, progress, and documentation. J Rheumatol 30:167-178.
11. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, Canesi B, Fumagalli M, Mastaglio C, Mathieu A, Fantini F 1993 The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123-128.
12. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH 2004 A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 34:747-754.
13. Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ 1996 Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101:341-348.
14. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967.
15. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
16. Siris ES, Lyles KW, Singer FR, Meunier PJ 2006 Medical management of Paget's disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res 21:P94-P98.
17. Papapoulos SE, Eekhoff EM, Zwinderman AH 2006 Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res 21:P88-P91.
18. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ 1999 Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rheum Engl Ed 66:4670-476.
19. Lyles KW 2003 What is "resistance" in Paget's disease of bone? Arthritis Rhum 48:2097-2099.
20. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S 1999 Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14:79-84.
21. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D 2005 Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908.
22. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR 2007 Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142-148.
23. Atkins RM, Yates AJ, Gray RE, Urwin GH, Hamdy NA, Beneton MN, Rosini S, Kanis JA 1987 Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res 2:273-279.
24. Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F 1998 Paget's disease of bone: Benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone 23:543-548.
25. Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V 2002 Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 20:55-58.
26. Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ 1990 Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). J Bone Miner Res 5:1231-1235.
27. Bombassei GJ, Yocono M, Raisz LG 1994 Effects of intravenous pamidronate therapy on Paget's disease of bone. Am J Med Sci 308:226-233.
28. Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, Kent GN, Bhagat CI, Price RI, Thompson RI, Nicholson GC 1996 Clinical, biochemical, haematological, and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2-year study. Bone 19:387-394.
29. Tucci JR, Bontha S 2001 Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract 7:423-429.
30. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 295:1301-1305.
31. Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P 1988 A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 85:207-212.
32. Gallacher SJ, Boyce BF, Patel U, Jenkins A, Ralston SH, Boyle IT 1991 Clinical experience with pamidronate in the treatment of Paget's disease of bone. Ann Rheum Dis 50:930-933.
33. Stuckey BG, Gutteridge DH, Stewart GO, Prince RL, Ward LC, Kent GN, Prince RI, Retallack RW, Bhagat CI, Nicholson GC, Thompson RI 1994 Intravenous pamidronate in Paget's disease-response is dependent on radiographic and biochemical severity. Semin Arthritis Rheum 23:286.
34. Cantrill JA, Anderson DC 1990 Treatment of Paget's disease of bone. Clin Endocrinol (Oxf) 32:507-518.
35. Cundy T, Wattic D, King AR 1996 High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58:6-8.
36. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF 1993 Mineralization defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460.
37. Boyce BF, Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT 1994 Mineralization defects after pamidronate for Paget's disease. Lancet 343:1231-1232.
38. Buckler HM, Mercer SJ, Davison CE, Hollis S, Richardson PC, Anderson DG 1998 Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone. Ann Rheum Dis 57:572.
39. Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F, Davie M, Fogelman I, Birbara CA, Moses AM, Lyles K, Selby P, Richardson P, Seaman J, Zelenakas K, Siris E 1999 Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study. Bone 24:81S-85S.
40. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterluty H, Scotlandi K, Kotz R, Micksche M, Berger W 2006 Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24:1145-1152.
41. Evdokiou A, Labrinidis A, Bouralexis S, Hays S, Findlay DM 2003 Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33:216-228.
42. Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D 2007 Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71:333-343.
43. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thièry JP, Gouin F, Rédini F 2005 Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37:74-86.
44. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Rédini F 2005 Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma of osteosarcoma-bearing mice. Cancer 104:2522-2529.